Neoadjuvant Nivolumab Plus Chemotherapy and Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer
This phase 2 nonrandomized controlled trial evaluates effectiveness and tolerance of neoadjuvant nivolumab, nab-paclitaxel, and carboplatin followed by response-adaptive therapy in patients with human papillomavirus−positive oropharyngeal cancer.